Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesare Gridelli

Showing results (81-90 of 357) with videos related to

Pageof 36
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 2, 2009
Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: a survey of the Italian Association of Thoracic Oncology (AIOT)Cesare Gridelli, Antonio Rossi, Filippo de Marinis
Current Oncology (Toronto, Ont.)|January 27, 2026
Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option?Paolo Maione, Francesco Jacopo Romano, Cesare Gridelli
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failureCesare Gridelli, Paolo Maione, Domenico Galetta, et al.
Expert Opinion on Pharmacotherapy|November 20, 2015
Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapyGiuseppe Santabarbara, Paolo Maione, Antonio Rossi, et al.
Expert Opinion on Investigational Drugs|March 9, 2026
Critique of phase II agents for non-small cell lung cancer: what is our clinical need and which agents have potential?Alessia Spagnuolo, Ilaria Spagnoletti, Emanuela Nuccio, et al.
European Journal of Radiology|June 7, 2017
Alternative imaging strategy of solitary pulmonary nodule by FDG PET/CT: Can be imagined a tailored PET?Marco Spadafora, Laura Evangelista, Cesare Gridelli, et al.
Cancers|March 13, 2025
New Treatment Strategies in Advanced Epidermal Growth Factor Receptor-Driven Non-Small Cell Lung Cancer: Beyond Single Agent OsimertinibPaolo Maione, Valentina Palma, Giuseppina Pucillo, et al.
Expert Opinion on Therapeutic Targets|August 20, 2024
Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?Paolo Maione, Valentina Palma, Giuseppina Pucillo, et al.
Journal of Thoracic Disease|July 20, 2018
Lung cancer resection in octogenarian patientsLorenzo Spaggiari, Francesco Petrella, Paolo Maione, et al.
The Oncologist|March 22, 2006
Combining targeted therapies and drugs with multiple targets in the treatment of NSCLCPaolo Maione, Cesare Gridelli, Teresa Troiani, et al.
Pageof 36

Showing results (81-90 of 357) with videos related to

Sort By:
Pageof 36
Lung Cancer (Amsterdam, Netherlands)|June 2, 2009
Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: a survey of the Italian Association of Thoracic Oncology (AIOT)Cesare Gridelli, Antonio Rossi, Filippo de Marinis
Current Oncology (Toronto, Ont.)|January 27, 2026
Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option?Paolo Maione, Francesco Jacopo Romano, Cesare Gridelli
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failureCesare Gridelli, Paolo Maione, Domenico Galetta, et al.
Expert Opinion on Pharmacotherapy|November 20, 2015
Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapyGiuseppe Santabarbara, Paolo Maione, Antonio Rossi, et al.
Expert Opinion on Investigational Drugs|March 9, 2026
Critique of phase II agents for non-small cell lung cancer: what is our clinical need and which agents have potential?Alessia Spagnuolo, Ilaria Spagnoletti, Emanuela Nuccio, et al.
European Journal of Radiology|June 7, 2017
Alternative imaging strategy of solitary pulmonary nodule by FDG PET/CT: Can be imagined a tailored PET?Marco Spadafora, Laura Evangelista, Cesare Gridelli, et al.
Cancers|March 13, 2025
New Treatment Strategies in Advanced Epidermal Growth Factor Receptor-Driven Non-Small Cell Lung Cancer: Beyond Single Agent OsimertinibPaolo Maione, Valentina Palma, Giuseppina Pucillo, et al.
Expert Opinion on Therapeutic Targets|August 20, 2024
Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?Paolo Maione, Valentina Palma, Giuseppina Pucillo, et al.
Journal of Thoracic Disease|July 20, 2018
Lung cancer resection in octogenarian patientsLorenzo Spaggiari, Francesco Petrella, Paolo Maione, et al.
The Oncologist|March 22, 2006
Combining targeted therapies and drugs with multiple targets in the treatment of NSCLCPaolo Maione, Cesare Gridelli, Teresa Troiani, et al.
Pageof 36